Synthesis and Initial in Vivo Studies with [(11)C]SB-216763: The First Radiolabeled Brain Penetrative Inhibitor of GSK-3.
暂无分享,去创建一个
Young T. Hong | Stephan A. Ohnmacht | X. Shao | T. Fryer | F. Aigbirhio | P. Scott | P. Sherman | P. Riss | Erin L. Cole | D. Williamson | Carole Quesada | Lei Li | V. Ferrari | Valentina Ferrari
[1] X. Shao,et al. Synthesis and evaluation of [(11)C]PyrATP-1, a novel radiotracer for PET imaging of glycogen synthase kinase-3β (GSK-3β). , 2014, Nuclear medicine and biology.
[2] U. Rix,et al. GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells. , 2014, ACS chemical biology.
[3] S. Hellberg,et al. AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans , 2013, Journal of neurochemistry.
[4] C. Pérez,et al. Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. , 2013, ACS chemical neuroscience.
[5] H. Weng,et al. The Role of Glycogen Synthase Kinase 3 Beta in Neuroinflammation and Pain. , 2013, Journal of pharmaceutics & pharmacology.
[6] Sven Hellberg,et al. Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimer's disease: design, synthesis, and characterization of pyrazines. , 2012, Journal of medicinal chemistry.
[7] Alan A. Wilson,et al. Towards the preparation of radiolabeled 1-aryl-3-benzyl ureas: Radiosynthesis of [(11)C-carbonyl] AR-A014418 by [(11)C]CO(2) fixation. , 2012, Bioorganic & medicinal chemistry letters.
[8] Ana Martínez,et al. GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS , 2011, Front. Mol. Neurosci..
[9] H. Eldar-Finkelman,et al. Synthesis and biological evaluation of glycogen synthase kinase 3 (GSK-3) inhibitors: an fast and atom efficient access to 1-aryl-3-benzylureas. , 2011, Bioorganic & medicinal chemistry letters.
[10] Manuela G. López,et al. The antinociceptive effects of AR-A014418, a selective inhibitor of glycogen synthase kinase-3 beta, in mice. , 2011, The journal of pain : official journal of the American Pain Society.
[11] G. Hutchins,et al. The first synthesis of [(11)C]SB-216763, a new potential PET agent for imaging of glycogen synthase kinase-3 (GSK-3). , 2011, Bioorganic & medicinal chemistry letters.
[12] M. Frech,et al. Novel indolylmaleimide acts as GSK-3beta inhibitor in human neural progenitor cells. , 2010, Bioorganic & medicinal chemistry.
[13] Jesús Avila,et al. Role of glycogen synthase kinase-3 in Alzheimer’s disease pathogenesis and glycogen synthase kinase-3 inhibitors , 2010, Expert review of neurotherapeutics.
[14] Simon Lovestone,et al. The GSK3 hypothesis of Alzheimer's disease , 2008, Journal of neurochemistry.
[15] M. Roh,et al. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. , 2006, Current drug targets.
[16] S. A. Thomson,et al. Synthesis and evaluation of novel heterocyclic inhibitors of GSK-3. , 2006, Bioorganic & medicinal chemistry letters.
[17] L. Meijer,et al. Synthesis and biological evaluation of novel phenylcarbazoles as potential anticancer agents. , 2006, Journal of medicinal chemistry.
[18] Alan A. Wilson,et al. Synthesis and ex vivo evaluation of carbon-11 labelled N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea ([11C]AR-A014418): a radiolabelled glycogen synthase kinase-3beta specific inhibitor for PET studies. , 2005, Bioorganic & medicinal chemistry letters.
[19] H. Manji,et al. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. , 2004, The international journal of neuropsychopharmacology.
[20] G. Kuo,et al. Design, synthesis, and biological evaluation of novel 7-azaindolyl-heteroaryl-maleimides as potent and selective glycogen synthase kinase-3β (GSK-3β) inhibitors , 2004 .
[21] Michel Goedert,et al. GSK3 inhibitors: development and therapeutic potential , 2004, Nature Reviews Drug Discovery.
[22] Kirk W. Johnson,et al. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. , 2004, Current pharmaceutical design.
[23] R. Jope,et al. The glamour and gloom of glycogen synthase kinase-3. , 2004, Trends in biochemical sciences.
[24] H. Manji,et al. AR-A 014418 , a selective GSK-3 inhibitor , produces antidepressant-like effects in the forced swim test , 2004 .
[25] S. A. Watkins,et al. Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors. , 2003, Bioorganic & medicinal chemistry letters.
[26] S. A. Watkins,et al. Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles. , 2003, Bioorganic & medicinal chemistry letters.
[27] S. A. Watkins,et al. Synthesis of quinolinyl/isoquinolinyl[a]pyrrolo [3,4-c] carbazoles as cyclin D1/CDK4 inhibitors. , 2003, Bioorganic & medicinal chemistry letters.
[28] Ana Martínez,et al. Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation , 2002, Medicinal research reviews.
[29] H. Eldar-Finkelman,et al. Glycogen synthase kinase 3: an emerging therapeutic target. , 2002, Trends in molecular medicine.
[30] P. Cohen,et al. GSK3 takes centre stage more than 20 years after its discovery. , 2001, The Biochemical journal.
[31] J W Yates,et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. , 2000, Chemistry & biology.
[32] E. Krebs,et al. Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice. , 1999, Diabetes.
[33] J. Brion,et al. Developmental expression and localization of glycogen synthase kinase-3β in rat brain , 1999, Journal of Chemical Neuroanatomy.
[34] J. Woodgett,et al. Molecular cloning and expression of glycogen synthase kinase‐3/factor A. , 1990, The EMBO journal.
[35] S. Eguchi,et al. Regioselectivity control in alkylation reactions of indolyl ambident anion , 1990 .
[36] C. Pyun,et al. Effect of solvent and cation on the reaction of organometallic derivatives of indole with methyl iodide , 1972 .
[37] D M DUNLOP,et al. The Antihistamine Drugs , 1949, The Journal of pharmacy and pharmacology.